Verapamil Overview
Verapamil is a non-dihydropyridine calcium channel blocker indicated primarily for hypertension and supraventricular tachycardia, with strict contraindications in severe left ventricular dysfunction, hypotension (SBP <90 mmHg), second/third-degree AV block, sick sinus syndrome (without pacemaker), and Wolff-Parkinson-White syndrome with atrial fibrillation/flutter. 1
Primary Indications
Hypertension
- First-line treatment for essential hypertension to reduce cardiovascular morbidity and mortality, particularly stroke risk 1
- Particularly effective in elderly patients and those with low plasma renin activity 2
- Preferred over beta-blockers in patients with asthma or chronic obstructive airway disease since it does not cause bronchoconstriction 2
Supraventricular Tachycardia
- Rate control for SVT and atrial fibrillation/flutter (in appropriate candidates) 3
- Specific first-line indication for fascicular ventricular tachycardia (verapamil-sensitive VT) 4
Off-Label Uses
Dosing Regimens
Oral Administration (Extended-Release)
For Hypertension:
- Initial dose: 180 mg once daily in the morning with food 1
- Lower starting dose of 120 mg daily may be warranted in elderly or small patients 1
- Maintenance range: 120-480 mg daily in divided or single doses with long-acting formulations 3
- Titrate upward weekly based on response: 180 mg → 240 mg daily → 180 mg AM + 180 mg PM → 240 mg AM + 120 mg PM → 240 mg every 12 hours 1
- Antihypertensive effects evident within first week 1
Intravenous Administration
For Acute Rate Control:
- Mean effective dose approximately 5.4 mg 7
- Critical safety point: Administer as SLOW infusion over 10-30 minutes, NOT as rapid push 4
- Rapid IV push has been associated with cardiovascular collapse, particularly in infants and compromised patients 4
Absolute Contraindications
The FDA label and guidelines are unequivocal about these contraindications 1:
- Severe left ventricular dysfunction/decompensated systolic heart failure
- Hypotension (systolic BP <90 mmHg) or cardiogenic shock
- Second- or third-degree AV block (unless functioning pacemaker present)
- Sick sinus syndrome (unless functioning pacemaker present)
- Atrial fibrillation/flutter with accessory bypass tract (WPW, Lown-Ganong-Levine syndromes)
- Known hypersensitivity to verapamil
- Contraindicated with dofetilide 3
Evidence Supporting Contraindications
A 1991 study demonstrated that patients with contraindications to verapamil experienced significantly higher incidence of adverse outcomes and drug failures 8. Specifically, contraindicated rhythms, low pretreatment blood pressure, and signs of congestive heart failure were each associated with increased risk of adverse sequelae 8.
However, recent 2025 data challenges the absolute nature of the heart failure contraindication: In 223 consecutive AF patients treated with IV verapamil, including 71 (31.8%) with heart failure and 28 (13.6%) with LVEF <50%, the drug appeared effective and relatively safe except in critically ill patients 7. Multivariate analysis showed that pre-treatment systolic BP and hemoglobin—but not LVEF or BNP—were independently associated with adverse events 7. This suggests the contraindication may be overly broad, though extreme caution remains warranted.
Monitoring Recommendations
Baseline Assessment
- EKG required before initiating therapy to screen for pre-existing conduction abnormalities 5
- Blood pressure measurement
- Assessment for heart failure signs/symptoms
- Liver function tests (verapamil can cause abnormal LFTs and rarely acute hepatic injury) 3
- Renal function
During Treatment
- Monitor for hypotension, bradycardia, and worsening heart failure 3
- For high-dose verapamil (≥480 mg/day for cluster headache): Consider Holter monitoring, though expert consensus is lacking 5
- Weekly blood pressure assessment during titration 1
- Liver function monitoring if abnormalities develop
Common Pitfalls to Avoid
Do NOT use rapid IV push administration—always give as slow infusion over 10-30 minutes to prevent cardiovascular collapse 4
Do NOT combine with other AV nodal blocking agents without extreme caution (beta-blockers, digoxin, diltiazem) due to additive negative chronotropic and inotropic effects 3, 9
Do NOT use in atrial flutter without concomitant AV nodal therapy to prevent 1:1 conduction 3
Beware of the infant contraindication exception: While guidelines state verapamil is contraindicated in infants, this is based on rapid IV push administration in compromised infants. For fascicular VT specifically, slow IV infusion can be used safely in infants without cardiovascular compromise 4
Adverse Effects
Most common:
- Hypotension (12.6% in recent study) 7
- Bradycardia
- Worsening heart failure in patients with pre-existing ventricular dysfunction
- Constipation (not emphasized in provided evidence but well-known)
Serious but rare:
- Pulmonary edema in hypertrophic cardiomyopathy patients 3
- Bradyarrhythmias (2/223 patients in recent study) 7
- Cardiovascular death (1.3% within 7 days in critically ill AF patients) 7
- Acute hepatic injury (rare) 3
Notable advantage: Does NOT cause reflex tachycardia, orthostatic hypotension, or tolerance development 2
Drug Interactions
Verapamil is a moderate CYP3A4 inhibitor and P-glycoprotein inhibitor 3:
Critical interactions requiring dose adjustment or avoidance:
- Digoxin: Reduce digoxin dose by 50%; monitor levels closely 3
- Simvastatin: Increased myopathy risk
- Dabigatran, edoxaban, rivaroxaban: Increased anticoagulant effect
- Flecainide: Monitor levels
- Cyclosporine, tacrolimus: Increased immunosuppressant levels
- Grapefruit juice: Avoid (increases verapamil levels) 3
Pharmacokinetics Considerations
- Low oral bioavailability (20%) due to high first-pass hepatic metabolism 9
- Accumulation occurs with multiple dosing, with decreased apparent oral clearance 9
- Active metabolite norverapamil reaches plasma concentrations approximating parent drug after oral administration 9
- Hepatic dysfunction or altered hepatic blood flow can significantly affect drug disposition 9